ADAPTSMART: Accelerated Development of Appropriate Patient Therapies

ADAPT SMART is a  platform funded by the European Union's IMI (Innovative Medicines Initiative) for the coordination of Medicines Adaptive Pathways to Patients (MAPPs) activities, involving multi-stakeholder approaches from research through to treatment outcomes. MAPPs seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashiion.

The European Medicines Agency has just hosted (17th - 18th  January 2017) at Canary Wharf in London an expert workshop on ADAPTSMART, with delegates from throughout the European Region, from the Japanese medicines agency and elsewhere.

Topics included:

- appropriate use of medicines

- timely access to innovative medicines and other interventions

- early access medicine schemes

- protected therapeutic schemes e.g. cancer access funds

- compassionate use

- expanded access pathways

- shortened timelines for approvals

- need for cross-border data-sharing and research

- international comparisons for consequences of inappropriate prescribing - non-compliance with treatment guidelines

- linkeing reimbursement to compliance with prescribing guidelines

See more on the ADAPTSMART website about key work packages and other aspects.